New Delhi: India is set to see the launch of Afrezza—the only rapid-acting, inhaled insulin to help control high blood sugar in adults with type 1 or type 2 diabetes—ten years after the ...

The announcement that inhaled insulin will soon be available in India has understandably generated a lot of excitement and ...

Mannkind Corporation expects to submit a request for a supplemental new drug application meeting to the US Food and Drug Administration for its inhaled human insulin (Afrezza Inhalation Powder).

MannKind Corporation announced today that it plans to meet with the FDA to discuss a potential supplemental new drug application (sNDA) for its inhaled insulin product, Afrezza, following positive ...

Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for ...

Even as the global diabetes war continues to rage, Indian pharmaceutical companies are emerging from the shadows, armed with ...

“The availability of Afrezza has the potential to help so many people in India living with diabetes in improving glycemic control via a non-injectable and convenient delivery of inhaled insulin ...

Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for the ...

“The availability of Afrezza has the potential to help so many people in India living with diabetes in improving glycemic control via a non-injectable and convenient delivery of inhaled insulin,” said ...